BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA
BridgeBio Pharma Inc. (NASDAQ:BBIO) is one of the best high short interest stocks with huge upside potential.
Bridgebio Pharma Inc. (BBIO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 22,055,375 | $762,454,314 | -13% | 2.42% |
| 2. | Farallon Capital Thomas Steyer | 5,731,000 | $198,120,670 | +37% | 1.1% |
| 3. | Laurion Capital Management Benjamin A. Smith | 2,978,167 | $102,955,234 | -21% | 2.59% |
| 4. | Citadel Investment Group Ken Griffin | 2,931,033 | $101,325,811 | +134% | 0.02% |
| 5. | Deep Track Capital David Kroin | 2,800,000 | $96,796,000 | +242% | 3.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 1,752 | $24,948.48 | 3,294 | 2021-12-29 | Filing | |
| $13.16 | 796 | $10,475.36 | 2,687 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 1,542 | 2021-12-28 | Filing | |
| $12.68 | 1,542 | $19,552.56 | 3,433 | 2021-12-28 | Filing | |
| $13.18 | 1,891 | $24,923.38 | 1,891 | 2021-12-28 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $42.73 | 20,000 | $854,514.00 | 955,686 | 2025-07-02 | Filing | |
| $42.89 | 1,600 | $68,628.00 | 975,686 | 2025-07-01 | Filing | |
| $42.51 | 18,400 | $782,092.00 | 977,286 | 2025-07-01 | Filing | |
| $42.73 | 20,000 | $854,536.00 | 4,758,447 | 2025-07-02 | Filing | |
| $42.88 | 1,700 | $72,902.97 | 4,778,447 | 2025-07-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 350,411 | $15,130,747 | 0.02% | |
| 2. | 38,605 | $1,666,963 | 0.04% | |
| 3. | 8,822 | $380,934 | 0.07% | |
| 4. | 2,200 | $94,996 | 0.04% | |
| 5. | 309 | $13,343 | 0.01% |
News See All
10 Best High Short Interest Stocks With Huge Upside Potential
Abby Yoder, JPMorgan Private Bank's chief equity strategist, joined CNBC's 'Closing Bell' on July 2 to discuss the market's momentum as stocks began the second half of the year. Yoder confirmed her continued...
BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights
In a statement, BridgeBio Pharma, Inc.
Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential.
Wolfe Research Initiates Coverage of BridgeBio Pharma (BBIO) with 'Outperform' Rating
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 10 biotech stocks screaming a buy. On June 17, Wolfe Research initiated coverage of the stock with an ‘Outperform’ rating and a $49 price target.
10 Biotech Stocks Screaming a Buy
The biotech sector has underperformed the overall market. Those are sentiments echoed by JPMorgan analyst Chris Schott, given the 10% year-to-date loss by the SPDR S&P Biotech ETF.
Billionaire Stan Druckenmiller's 10 Stock Picks with Huge Upside Potential
Stanley Druckenmiller, an American billionaire investor, is the founder of Duquesne Capital.
BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is one of the 13 Biotech Stocks with Huge Upside Potential. In a recent report, Raghuram Selvaraju, an expert at H.C.
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
BMO Maintains Hold on BridgeBio (BBIO) Amid Intensifying Competition
On June 3, BMO Capital Markets analyst Kostas Biliouris reiterated a Hold rating on BridgeBio Pharma Inc. (NASDAQ:BBIO) with an unchanged price target of $37.
Billionaire Hedge Funds
